2018阿立哌唑对精神分裂症患者血清神经元特异性烯醇化酶、S100B蛋白
[摘要] 目的 探?阿立哌唑对精神分裂症患者血清神经元特异性烯醇化酶（NSE）、S100B蛋白和髓鞘碱性蛋白（MBP）水平的影响及疗效。 方法 选取住院治疗的精神分裂症患者86例，将其随机分为观察组和对照组。观察组患者予以阿立哌唑片治疗，先予5 mg/次，1次/d，2周内逐渐增加剂量至维持量15 mg/d；对照组予以奥氮平片治疗，先予5 mg/次，1次/d，2周内逐渐增加剂量至维持量（10～20）mg/d。两组均连用12周。观察两组治疗前与治疗12周后血清MBP、S100B蛋白和NSE指标变化情况，并比较其效果和安全性。 结果 治疗12周后，两组患者血清NSE、S100B蛋白和MBP水平较前均有明显下降（P http://[关键词] 精神分裂症；阿立哌唑；奥氮平；神经元特异性烯醇化酶（NSE）；S100B蛋白；髓鞘碱性蛋白（MBP）
[中图分类号] R749.3 [文献标识码] A [文章编号] 1673-9701（2017）33-0001-04
Objective To investigate the effect of aripiprazole on the levels of serum neuron-specific enolase（NSE）， S100B protein and myelin basic protein（MBP） in schizophrenic patients and its curative effect. Methods 86 patients with schizophrenia who were hospitalized in our hospital were randomly divided into observation group and control group. Patients in the observation group were given aripiprazole tablet， with initial dose of 5 mg， once a day. The dose was gradually increased to the maintenance dose of 15 mg/d； patients in the control group were given olanzapine tablets， with the initial dose of 5 mg， once a day. The dose was gradually increased to the maintenance dose of 10-20 mg/d. The administration was kept for 12 weeks in both groups. The changes of serum MBP， S100B protein and NSE were observed before treatment and 12 weeks after treatment in both groups， and its efficacy and safety were compared. Results After 12 weeks of treatment， serum NSE， S100B protein and MBP levels were significantly decreased in both groups compared with those before treatment（P
页:
[1]